A Text Messaging Intervention to Reduce Perinatal Depression Risk
Launched by UNIVERSITY OF MASSACHUSETTS, WORCESTER · Nov 1, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help pregnant individuals who might be at risk for depression. Researchers are testing a text messaging program designed to provide support and information to help reduce the chances of experiencing a major depressive episode. Participants will receive personalized text messages and have access to a peer chat feature, allowing them to connect with others and share experiences. The program also includes links to helpful resources based on proven methods for treating depression.
To join this study, participants need to be English-speaking females aged 16 and older who are at risk for depression, which can be determined through a simple questionnaire. They should be willing to use a smartphone to receive text messages. However, individuals currently experiencing severe depression, those planning to terminate their pregnancy, or those receiving other mental health treatment cannot participate. This trial is currently recruiting participants, and it offers a unique opportunity for support during pregnancy.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • English speaking
- • "At risk" as determined by an Edinburgh Postnatal Depression Scale score of at least 9, or an average score \>3 on the 6-item Medical Outcomes Social Support Survey or history of depression in pregnancy or postpartum depression
- • At least age 16
- • Are willing and able to provide informed consent
- • Are willing to use a smart phone to receive texts
- Exclusion Criteria:
- • In a major depressive episode
- • Planning on terminating pregnancy
- • Have panic disorder or substance use disorder
- • Currently in behavioral health care treatment
- • Blind individuals
- • Permanently living in an institutional setting
About University Of Massachusetts, Worcester
The University of Massachusetts Worcester is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the university integrates cutting-edge scientific inquiry with a commitment to improving patient outcomes. Its collaborative approach engages a diverse range of experts, fostering interdisciplinary research that addresses pressing health challenges. With a focus on ethical standards and regulatory compliance, the University of Massachusetts Worcester plays a pivotal role in translating scientific discoveries into practical applications that enhance medical practice and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Worcester, Massachusetts, United States
Patients applied
Trial Officials
Kimberly Yonkers, MD
Principal Investigator
UMass Chan Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported